Who to call at Medicus Pharma, and when

Fundz watches for the moments Medicus Pharma starts buying, and tells you who to reach.

An alert the day Medicus Pharma raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Medicus Pharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Medicus Pharma. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Medicus Pharma Ltd. Enters Co-Development and License Agreement with Pfizer

Sep 03, 2026

Contract Type

licensing

West ConshohockenBiotechnologyHealthcareTherapeutics

Description

On September 2, 2026, Medicus Pharma Ltd. entered into a Co-Development and License Agreement with Pfizer Inc. This agreement grants Medicus Pharma an exclusive, sublicensable, royalty-bearing license under specified Pfizer patent rights. The agreement aims to foster collaboration between the two companies in pharmaceutical development.

Company Information

Company

Medicus Pharma

Location

100 KING STREET WEST

West Conshohocken, Pennsylvania, United States

About

Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is currently advancing the clinical development program of its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC). Medicus is also developing Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer. D-MNA and Teverelix, collectively represent ~$8 billion in potential market opportunity.